TMO Thermo Fisher Scientific Inc Common Stock
Про Thermo Fisher Scientific Inc Common Stock Огляд компанії з Wikipedia
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Детальніше
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
It ranked 106th on the Fortune 500 list based on its 2025 annual revenue of $44.556 billion.
History
Predecessors and merger
Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos received a PhD from MIT in mechanical engineering and Nomikos was a Harvard Business School graduate. The company focused on providing analytical and laboratory products.
Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.
On May 8, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific, and had about 30,000 employees, and reported US$9 billion in combined revenue. On November 9, 2006, the companies announced that the merger had been completed. However, the Federal Trade Commission ruled that this acquisition was anti-competitive regarding centrifugal evaporators, requiring Fisher to divest Genevac. In April 2007, Genevac was sold to Riverlake Partners LLC and the merger closed with FTC approval.
The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene).
Acquisition history
In 1990, Thermo Fisher Scientific (then known as Thermo Instrument Systems) acquired mass spectrometer manufacturer Finnigan Instrument Corporation.
In 2003, the company (then Fisher Scientific International) acquired Perbio Science, a transaction that included brands such as Pierce Biotechnology, HyClone and Endogen.
In April 2006, BioImage was acquired by Thermo Fisher Scientific. The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008. BioImage was established in 1993 as a drug discovery research unit led by Ole Thastrup within Novo Nordisk, from which it spun out of in 1999. It had specialized in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays.
In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.
In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash.
In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing. Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems. The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition.
In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs manufactures, and delivers technologies used in bioprocessing. In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September
In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.
In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction was completed a day later. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. As of 2017, the company had revenues of $20.9 billion, and was a Fortune 500 company.
In September 2018, Thermo Fisher Scientific announced it had signed a definitive agreement with Becton, Dickinson and Company (BDX) to acquire their Advanced Bioprocessing business. This BD business had annualized revenue of approximately $100 million; as of October 16, 2018, it had been integrated into Thermo Fisher's Life Sciences Solutions Segment.
In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio. In May 2019, Thermo Fisher Scientific partnered with MMJ International Holdings to manufacture drug products developed by MMJ for the treatment of multiple sclerosis and Huntington's disease. In June, the business announced it would acquire mass spectrometry software provider, HighChem.
In March 2020, Thermo Fisher Scientific received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic. Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to
support the development and production of new mRNA-based COVID-19 vaccines.
In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion. In July, the offer for Qiagen was raised from €39 to €43 per share (€11.3 billion in total). On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement.
In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies. In December the business announced it would acquire Phitonex, Inc.
In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million.
In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. PPD generated $4.7 billion in revenue during FY 2020, and this transaction, which values their company at approximately $20.9 billion. In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products.
In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. PeproTech became part of Thermo Fisher’s biosciences business and was integrated into the Life Sciences Solutions Segment.
In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6 billion from Nordic Capital. The acquisition completed in January 2023.
In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash. In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash).
In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion.
In February 2025, Thermo Fisher announced the acquisition of Solventum’s purification and filtration business for $4.1 billion.
In July 2025, Thermo Fisher added drug manufacturing capabilities in the United States through its purchase of a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.
In October 2025, Thermo Fisher announced a deal to acquire Clario Holdings—an endpoint data management solutions provider—for $8.88 billion in cash from a shareholder group including Novo Holding. The transaction was expected to close mid-2026.
Leadership
Marc N. Casper has been Chief Executive Officer of Thermo Fisher Scientific since October 2009, and was elected Chairman of the Board in February 2020. He also served as President from 2009 until March 2026. He joined the company in 2001 as President of the Life Sciences sector of Thermo Electron. Casper was named Senior Vice President in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger creating Thermo Fisher Scientific in 2006, he was named Executive Vice President and President of its Analytical Technologies business, and in 2008 he became the company’s Chief Operating Officer.
Prior to joining Thermo Fisher, Casper served as President, Chief Executive Officer and a Director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as President–Americas. He began his career as a strategy consultant at Bain & Company and later joined Bain Capital.
Partnerships
In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region.
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus.
In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration
agreement with Moderna, Inc. The collaboration was designed to scale up the
manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA
products.
In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients.
In November 2023, Thermo Fisher partnered with Flagship Pioneering, a biotechnology company. Together, they plan to create companies in the biotechnology field.
In January 2025, Thermo Fisher partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study. Using the Olink Explore platform, UKB-PPP seeks to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose, and treat diseases.
In February 2025, Thermo Fisher entered a 10-year virtual power purchase agreement (VPPA) with X-ELIO to secure 118 megawatts of solar energy, moving its European operations closer to a 100% renewable electricity goal.
In June 2025, Thermo Fisher partnered with the Regeneron Genetics Center which selected the Olink Explore platform for large-scale proteomics investigation involving nearly 200,000 patient samples aiming to unlock new insights into the dynamic biology and mechanisms of human disease.
Controversies
Xinjiang and Tibet
In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities. In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang.
In 2022, following reports that Thermo Fisher Scientific had sold products to police in the Tibet Autonomous Region, the Inter-Parliamentary Alliance on China called on governments to "investigate and suspend commercial activities with companies providing the PRC government with technologies to carry out biometric surveillance in the Uyghur Region, Tibet and elsewhere in the PRC, including the PRC state backed BGI Group and US firm Thermo Fisher." Thermo Fisher Scientific subsequently halted sales of DNA collection kits in Tibet.
HeLa cells
In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research. Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more.
In May 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit. In late July 2023, with the motion to dismiss still outstanding, the court ordered the parties to attend a settlement conference. Soon after that, settlement of the suit, with undisclosed terms, was announced.
Mexican plant
In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by the Gulf Cartel. According to Opengate Capital, the company withheld important documents and pressured employees into concealing the presence of the drug cartel.
Image manipulation
In May 2026, scientists found that a large number of images from Thermo Fisher Scientific's catalog had been manipulated, with sections of the images blanked out and duplicated with the same part of the picture copied into multiple places. The images were claimed to validate the effectiveness of antibody products which have uses including Western blots.
Джерело: Wikipedia (Англійська), CC BY-SA 4.0 · Переглянути на Wikipedia ↗
TMO Знімок акцій Ціна, ринкова капіталізація, P/E, EPS, ROE, борг/власний капітал, діапазон 52 тижнів
TMO Графік ціни акцій Денні OHLCV з технічними індикаторами — панування, масштабування та налаштування вашого представлення
10-річна ефективність Тренди виручки, чистого прибутку, маржі та EPS
Оцінка Співвідношення P/E, P/S, P/B, EV/EBITDA — акція дорога чи дешева?
Прибутковість Валова, операційна та чиста маржа; ROE, ROA, ROIC
Фінансове здоровʼя Борг, ліквідність, платоспроможність — міцність балансу
Зростання Зростання виручки, EPS та чистого прибутку: рік до року, 3-річний CAGR, 5-річний CAGR
Ефективність капіталу Оборотність активів, оборотність запасів, оборотність дебіторської заборгованості
Дивіденди Дивідендна дохідність, коефіцієнт виплат, історія дивідендів, 5-річний CAGR
| Дата екс-дивіденду | Сума |
|---|---|
| 15 червня 2026 р. | $0,4700 |
| 13 березня 2026 р. | $0,4700 |
| 15 грудня 2025 р. | $0,4300 |
| 15 вересня 2025 р. | $0,4300 |
| 13 червня 2025 р. | $0,4300 |
| 14 березня 2025 р. | $0,4300 |
| 13 грудня 2024 р. | $0,3900 |
| 13 вересня 2024 р. | $0,3900 |
| 14 червня 2024 р. | $0,3900 |
| 14 березня 2024 р. | $0,3900 |
| 14 грудня 2023 р. | $0,3500 |
| 14 вересня 2023 р. | $0,3500 |
| 14 червня 2023 р. | $0,3500 |
| 14 березня 2023 р. | $0,3500 |
| 14 грудня 2022 р. | $0,3000 |
| 14 вересня 2022 р. | $0,3000 |
| 14 червня 2022 р. | $0,3000 |
| 15 березня 2022 р. | $0,3000 |
| 14 грудня 2021 р. | $0,2600 |
| 14 вересня 2021 р. | $0,2600 |
TMO Консенсус аналітиків Бичачі та ведмежі думки аналітиків, 12-місячна цільова ціна, потенціал зростання
- Активна купівля 11 30,6%
- Купівля 18 50,0%
- Утримувати 7 19,4%
- Продаж 0 0,0%
- Активний продаж 0 0,0%
12-місячна цільова ціна
26 аналітиків · 2026-08-14Історія прибутків EPS фактичний проти прогнозу, сюрприз %, коефіцієнт перевищення, дата наступного звіту про прибутки
| Період | EPS Actual | EPS прогноз | Сюрприз |
|---|---|---|---|
| 30 червня 2026 р. | $6.03 | $5.77 | 0.26% |
| 31 березня 2026 р. | $5.44 | $5.29 | 0.15% |
| 31 грудня 2025 р. | $6.57 | $6.51 | 0.06% |
| 30 вересня 2025 р. | $5.79 | $5.55 | 0.24% |
| 30 червня 2025 р. | $5.36 | $5.28 | 0.08% |
| 31 березня 2025 р. | $5.15 | $5.15 | -0.00% |
Порівняння з аналогами (підгалузь GICS) Ключові показники порівняно з аналогами в секторі
| Тікер | Капіталізація | P/E | Виручка рік до року | Чиста маржа | ROE | Валова маржа |
|---|---|---|---|---|---|---|
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | — |
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | — |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
Повні фундаментальні показники Усі показники за роками — звіт про прибутки та збитки, баланс, рух грошових коштів
Звіт про прибутки та збитки 17
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $8.21B | $7.58B | |
| R&D Expense | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1.00B | $967M | · | $754M | $692M | |
| SG&A Expense | $8.73B | $8.60B | $8.45B | $8.99B | $8.01B | $6.93B | $6.14B | $6.06B | · | $4.97B | $4.61B | |
| Operating Expenses | $36.81B | $35.54B | $36.00B | $36.52B | $29.18B | $24.42B | $20.95B | $20.57B | · | $15.82B | $14.63B | |
| Operating Income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | · | $2.46B | $2.34B | |
| Interest Expense | · | · | $1.38B | $726M | $536M | $553M | $676M | $667M | · | $469M | $415M | |
| Interest Income | $993M | $1.08B | $879M | $272M | $43M | $65M | $224M | $137M | · | $48M | $31M | |
| Other Non-op | $-12M | $12M | $-65M | $-104M | $-694M | $-76M | $-70M | $9M | · | $-13M | $-16M | |
| Pretax Income | $7.31B | $7.04B | $6.30B | $7.83B | $8.84B | $7.23B | $4.07B | $3.26B | · | $2.02B | $1.94B | |
| Income Tax | $547M | $657M | $284M | $703M | $1.11B | $850M | $374M | $324M | · | $-1M | $-44M | |
| Net Income | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | · | · | · | · | |
| EPS (Basic) | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 | $9.24 | $7.31 | · | $5.12 | $4.96 | |
| EPS (Diluted) | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | · | $5.09 | $4.92 | |
| Shares (Basic) | 377,000,000 | 382,000,000 | 386,000,000 | 392,000,000 | 394,000,000 | 396,000,000 | 400,000,000 | 402,000,000 | · | 395,000,000 | 399,000,000 | |
| Shares (Diluted) | 378,000,000 | 383,000,000 | 388,000,000 | 394,000,000 | 397,000,000 | 399,000,000 | 403,000,000 | 406,000,000 | · | 397,000,000 | 402,000,000 | |
| EBITDA | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $6.05B | · | $4.21B | $4.02B |
Баланс 28
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.85B | $4.01B | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B | $2.10B | · | $786M | $452M | |
| Short-term Investments | $253M | $1.56B | $3M | · | · | · | · | · | · | · | · | |
| Receivables | $8.90B | $8.19B | $8.22B | $8.12B | $7.98B | $5.74B | $4.35B | $4.14B | $3.87B | $3.05B | $2.54B | |
| Inventory | $5.42B | $4.98B | $5.09B | $5.63B | $5.05B | $4.03B | $3.37B | $3.00B | $2.72B | $2.21B | $1.99B | |
| Other Current Assets | $2.61B | $1.96B | $1.76B | $1.64B | $1.64B | $1.13B | $1.17B | $922M | $1.47B | $595M | $534M | |
| Current Assets | $28.71B | $22.14B | $24.59B | $25.23B | $20.11B | $21.96B | $11.89B | $10.62B | · | $7.02B | $5.74B | |
| PP&E (Net) | $10.56B | $9.31B | $9.45B | $9.28B | $8.33B | $5.91B | $4.75B | $4.17B | · | $2.58B | $2.45B | |
| PP&E (Gross) | $18.38B | $16.06B | $15.52B | $14.27B | $12.59B | $9.58B | $7.76B | $6.82B | · | $4.42B | $4.11B | |
| Accum. Depreciation | $7.82B | $6.75B | $6.08B | $4.99B | $4.26B | $3.67B | $3.02B | $2.65B | · | $1.84B | $1.66B | |
| Goodwill | $49.36B | $45.85B | $44.02B | $41.20B | $41.92B | $26.04B | $25.71B | $25.35B | · | $21.33B | $18.83B | |
| Intangibles | $15.84B | $15.53B | $16.67B | $17.44B | $20.11B | $12.69B | $14.01B | $14.98B | · | $13.97B | $12.76B | |
| Other Non-current Assets | $5.87B | $4.49B | $4.00B | $4.01B | $4.64B | $2.46B | $2.01B | $1.12B | $1.17B | $1.01B | $1.06B | |
| Total Assets | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Accounts Payable | $3.62B | $3.08B | $2.87B | $3.38B | $2.87B | $2.17B | $1.92B | $1.61B | · | $926M | $822M | |
| Short-term Debt | · | · | · | · | · | · | · | $693M | · | $953M | $50M | |
| Current Liabilities | $15.19B | $13.33B | $14.01B | $17.01B | $13.44B | $10.30B | $6.20B | $6.15B | · | $4.87B | $4.15B | |
| Capital Leases | $1.20B | $1.24B | $1.24B | $1.31B | $1.20B | $626M | $571M | · | · | · | · | |
| Deferred Tax | $1.49B | $1.27B | $1.92B | $2.85B | $3.84B | $1.79B | $2.19B | $2.27B | $2.71B | $2.56B | $2.62B | |
| Other Non-current Liabilities | $4.27B | $3.99B | $4.64B | $4.24B | $4.54B | $3.33B | $3.24B | $2.52B | $2.64B | $1.57B | $1.29B | |
| Long-term Debt | $39.17B | $31.07B | $34.73B | $34.28B | $34.67B | $21.73B | $17.75B | $18.99B | · | · | · | |
| Total Debt | · | · | · | · | · | $19.11B | $17.08B | $693M | · | $953M | $50M | |
| Common Stock | $445M | $444M | $442M | $441M | $439M | $437M | $434M | $432M | · | $415M | $412M | |
| Retained Earnings | $59.16B | $53.10B | $47.36B | $41.91B | $35.43B | $28.12B | $22.09B | $18.70B | $16.03B | $13.93B | $12.14B | |
| Treasury Stock | $22.31B | $19.23B | $15.13B | $12.02B | $8.92B | $6.82B | $5.24B | $3.67B | · | $2.31B | $1.01B | |
| AOCI | $-2.45B | $-2.70B | $-3.22B | $-3.10B | $-2.33B | $-2.81B | $-2.68B | $-2.50B | $-2.09B | $-2.64B | $-2.00B | |
| Stockholders' Equity | $53.41B | $49.58B | $46.73B | $43.98B | $40.79B | $34.51B | $29.68B | $27.59B | · | $21.54B | $21.35B | |
| Liabilities + Equity | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Shares Outstanding | 445,000,000 | 444,000,000 | 442,000,000 | 441,000,000 | 439,000,000 | 437,000,000 | 434,000,000 | · | · | · | · |
Грошовий потік 19
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $2.27B | · | $1.76B | $1.69B | |
| Stock-based Comp | $310M | $301M | $278M | $307M | $230M | $196M | $181M | $181M | · | $133M | $125M | |
| Deferred Tax | $-639M | $-1.21B | $-1.30B | $-997M | $-645M | $-269M | $-499M | $-474M | · | $-639M | $-600M | |
| Amort. of Intangibles | $1.73B | $1.95B | $2.34B | $2.40B | $1.76B | $1.67B | $1.71B | $1.74B | · | $1.38B | $1.31B | |
| Restructuring | $197M | $97M | $194M | $68M | $37M | $51M | $52M | $88M | · | $167M | $90M | |
| Operating Cash Flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B | · | $3.26B | $2.94B | |
| CapEx | $1.52B | $1.40B | $1.48B | $2.24B | $2.52B | $1.47B | $926M | $758M | · | $444M | $423M | |
| Investing Cash Flow | $-4.05B | $-5.84B | $-5.14B | $-2.16B | $-21.93B | $-1.51B | $-1.49B | $-1.25B | · | $-5.52B | $-1.09B | |
| Debt Issued | $7.76B | $1.20B | $5.94B | $3.19B | $18.14B | $3.46B | $5.64B | $690M | · | $7.60B | $1.80B | |
| Net Debt Issued | $5.35B | $-2.40B | $160M | $2.82B | $6.40B | $2.75B | $-722M | $-1.36B | · | $3.27B | $-1.98B | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | $0 | $0 | |
| Stock Repurchased | $3.00B | $4.00B | $3.00B | $3.00B | $2.00B | $1.50B | $1.50B | $500M | · | $1.25B | $500M | |
| Net Stock Activity | $-3.00B | $-4.00B | $-3.00B | $-3.00B | $-2.00B | $-1.50B | $-1.50B | $-500M | · | $-1.25B | $-500M | |
| Dividends Paid | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M | |
| Financing Cash Flow | $1.80B | $-6.79B | $-3.62B | $-2.81B | $6.58B | $959M | $-3.12B | $-2.24B | · | $2.76B | $-2.62B | |
| Net Change in Cash | $5.84B | $-4.06B | $-440M | $4.05B | $-5.84B | $7.91B | $305M | $756M | · | $345M | $-898M | |
| Taxes Paid | $1.78B | $1.83B | $1.48B | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | · | $2.71B | $2.39B | |
| Levered FCF | · | · | $5.61B | $6.25B | $6.32B | $6.33B | $3.43B | $3.18B | · | $2.24B | $1.97B |
Прибутковість 7
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 15.5% | · | 13.4% | 13.8% | |
| Net Margin | 15.0% | 14.8% | 13.9% | 15.5% | 19.7% | · | · | · | · | · | · | |
| Pretax Margin | 16.4% | 16.4% | 14.7% | 17.4% | 22.6% | 22.4% | 15.9% | 13.4% | · | 11.1% | 11.4% | |
| EBITDA Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 24.8% | · | 23.0% | 23.7% | |
| ROA | 6.5% | 6.4% | 6.1% | 7.2% | 9.4% | · | · | · | · | · | · | |
| ROE | 13.0% | 13.2% | 13.1% | 16.4% | 19.9% | · | · | · | · | · | · | |
| ROIC | 13.4% | 13.4% | 14.0% | 17.4% | 21.5% | 12.8% | 8.9% | 12.0% | · | 10.9% | 11.2% |
Ліквідність та платоспроможність 5
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 1.7 | 1.8 | 1.5 | 1.5 | 2.1 | 1.9 | 1.7 | · | 1.4 | 1.4 | |
| Quick Ratio | 1.3 | 1.0 | 1.2 | 1.0 | 0.9 | 1.6 | 1.1 | 1.0 | · | 0.8 | 0.7 | |
| Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | 0.0 | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | · | · | · | · | |
| Interest Coverage | · | · | 5.0 | 11.6 | 18.7 | 14.1 | 6.8 | 5.7 | · | 5.2 | 5.6 |
Ефективність 3
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | · | 3.9 | 3.9 | |
| Receivables Turnover | 5.2 | 5.2 | 5.2 | 5.6 | 5.7 | 6.4 | 6.0 | 6.1 | · | 6.5 | 6.8 |
Темпи зростання 10
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | 0.05% | -4.6% | 14.5% | 21.7% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.27% | 3.0% | 10.0% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 7.3% | 7.0% | -12.4% | -9.4% | 21.9% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 0.21% | -5.3% | -1.1% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.1% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 5.8% | 5.7% | -13.9% | -9.9% | 21.2% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.2% | -6.4% | -2.0% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 1.0% | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 13.5% | · | · | · | · | · | · | · | · | · | · |
Оцінка (TTM) 12
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Net Income TTM | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | $1.48B | · | $1.48B | $1.48B | |
| Market Cap | $257.86B | $230.98B | $234.61B | $242.85B | · | · | · | · | · | · | · | |
| P/E | 32.7 | 31.5 | 34.4 | 31.2 | 34.3 | 29.2 | 35.4 | 30.9 | · | 27.7 | 28.8 | |
| P/S | 5.8 | 5.4 | 5.5 | 5.4 | · | · | · | · | · | · | · | |
| P/B | 4.8 | 4.7 | 5.0 | 5.5 | · | · | · | · | · | · | · | |
| P / Cash Flow | 33.0 | 26.7 | 27.9 | 26.5 | · | · | · | · | · | · | · | |
| P / FCF | 41.0 | 31.8 | 33.9 | 35.1 | · | · | · | · | · | · | · | |
| Dividend Yield | 0.25% | 0.25% | 0.22% | 0.19% | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | 2.9% | 3.2% | 2.9% | 3.4% | 2.8% | 3.2% | · | 3.6% | 3.5% | |
| Payout Ratio | 9.5% | 9.2% | 8.8% | 6.5% | 5.1% | · | · | · | · | · | · | |
| Annual Payout | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M |
Звіт про прибутки та збитки 16
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.86B | $10.36B | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B | $10.57B | $10.71B | $11.45B | |
| R&D Expense | $364M | $336M | $357M | $346M | $352M | $342M | $374M | $346M | $339M | $331M | $327M | $319M | $346M | $391M | |
| SG&A Expense | $2.33B | $2.18B | $2.35B | $2.16B | $2.14B | $2.08B | $2.20B | $2.10B | $2.11B | $2.18B | $2.13B | $2.05B | $2.12B | $2.30B | |
| Operating Expenses | $9.91B | $9.14B | $9.96B | $9.18B | $9.02B | $8.65B | $9.38B | $8.76B | $8.72B | $8.68B | $9.03B | $8.71B | $9.15B | $9.59B | |
| Operating Income | $2.09B | $1.86B | $2.25B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B | $1.82B | $1.66B | $1.85B | $1.86B | $1.56B | $1.86B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $363M | · | $359M | $300M | · | |
| Interest Income | $207M | $233M | $259M | $234M | $297M | $203M | $227M | $277M | $295M | $279M | $309M | $246M | $146M | $150M | |
| Other Non-op | $31M | $-9M | $6M | $-2M | $-19M | $3M | $13M | $-16M | $5M | $10M | $-33M | $14M | $-46M | $35M | |
| Pretax Income | $1.92B | $1.73B | $2.15B | $1.83B | $1.71B | $1.62B | $1.94B | $1.74B | $1.76B | $1.59B | $1.74B | $1.76B | $1.36B | $1.78B | |
| Income Tax | $167M | $70M | $153M | $207M | $92M | $95M | $149M | $99M | $128M | $281M | $133M | $53M | $46M | $173M | |
| Net Income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B | $1.55B | $1.33B | $1.65B | $1.70B | $1.29B | $1.57B | |
| EPS (Basic) | $4.68 | $4.44 | $5.22 | $4.28 | $4.28 | $3.99 | $4.80 | $4.26 | $4.05 | $3.47 | $4.21 | $4.44 | $3.34 | $4.03 | |
| EPS (Diluted) | $4.68 | $4.43 | $5.21 | $4.27 | $4.28 | $3.98 | $4.78 | $4.25 | $4.04 | $3.46 | $4.20 | $4.42 | $3.32 | $4.01 | |
| Shares (Basic) | 371,000,000 | 372,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 378,000,000 | -764,000,000 | 382,000,000 | 382,000,000 | 382,000,000 | 0 | 386,000,000 | 386,000,000 | 0 | |
| Shares (Diluted) | 371,000,000 | 373,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 379,000,000 | -768,000,000 | 384,000,000 | 383,000,000 | 384,000,000 | 0 | 388,000,000 | 388,000,000 | -1,000,000 | |
| EBITDA | $2.09B | $1.86B | · | $1.94B | $1.83B | $1.72B | · | $1.84B | $1.82B | $1.66B | · | $1.86B | $1.56B | · |
Баланс 26
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.06B | $3.25B | $9.85B | $1.98B | $4.58B | $4.13B | $4.01B | $4.64B | $7.07B | $5.50B | · | $6.15B | $3.48B | · | |
| Short-term Investments | $0 | $2M | $253M | $1.56B | $1.81B | $1.81B | $1.56B | $2.00B | $1.75B | $1.75B | · | · | · | · | |
| Receivables | $9.45B | $9.20B | $8.90B | $8.91B | $8.59B | $8.46B | $8.19B | $8.26B | $7.94B | $7.93B | · | $8.37B | $7.92B | · | |
| Inventory | $5.63B | $5.50B | $5.42B | $5.75B | $5.56B | $5.22B | $4.98B | $5.43B | $5.20B | $5.13B | · | $5.40B | $5.66B | · | |
| Other Current Assets | $2.54B | $2.68B | $2.61B | $2.47B | $2.60B | $2.39B | $1.96B | $1.91B | $2.02B | $1.90B | · | $1.70B | $1.77B | · | |
| Current Assets | $23.36B | $22.32B | $28.71B | $22.30B | $24.58B | $23.38B | $22.14B | $23.78B | $25.48B | $23.64B | · | $23.09B | $20.21B | · | |
| PP&E (Net) | $10.76B | $10.66B | $10.56B | $10.18B | $9.63B | $9.33B | $9.31B | $9.41B | $9.28B | $9.32B | · | $9.17B | $9.35B | · | |
| PP&E (Gross) | · | · | $18.38B | · | · | · | $16.06B | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $7.82B | · | · | · | $6.75B | · | · | · | · | · | · | · | |
| Goodwill | $54.83B | $55.19B | $49.36B | $49.29B | $47.25B | $46.49B | $45.85B | $46.73B | $43.84B | $43.84B | $44.02B | $43.58B | $43.14B | $41.20B | |
| Intangibles | $18.61B | $19.15B | $15.84B | $16.24B | $15.15B | $15.32B | $15.53B | $16.26B | $15.52B | $16.05B | · | $17.09B | $17.97B | · | |
| Other Non-current Assets | $5.62B | $5.97B | $5.87B | $5.02B | $4.62B | $4.52B | $4.49B | $4.18B | $4.38B | $4.24B | · | $4.12B | $3.98B | · | |
| Total Assets | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.66B | $97.15B | |
| Accounts Payable | $3.27B | $3.34B | $3.62B | $3.12B | $2.98B | $3.05B | $3.08B | $2.61B | $2.55B | $2.56B | · | $2.51B | $2.80B | · | |
| Current Liabilities | $15.07B | $14.62B | $15.19B | $14.89B | $12.72B | $13.17B | $13.33B | $14.60B | $14.77B | $13.94B | · | $14.16B | $15.88B | · | |
| Capital Leases | · | · | $1.20B | · | · | · | $1.24B | · | · | · | · | · | · | · | |
| Deferred Tax | $1.58B | $2.11B | $1.49B | $842M | $624M | $1.04B | $1.27B | $1.12B | $1.52B | $1.81B | · | $2.62B | $2.98B | · | |
| Other Non-current Liabilities | $4.54B | $4.42B | $4.27B | $4.28B | $4.27B | $3.97B | $3.99B | $4.34B | $4.39B | $4.57B | · | $4.33B | $4.23B | · | |
| Long-term Debt | $42.28B | $42.95B | $39.17B | $35.48B | $35.03B | $33.99B | $31.07B | $35.11B | $35.20B | $35.39B | · | $35.08B | $35.05B | · | |
| Common Stock | $446M | $445M | $445M | $445M | $444M | $444M | $444M | $444M | $443M | $443M | · | $442M | $441M | · | |
| Retained Earnings | $62.19B | $60.63B | $59.16B | $57.35B | $55.90B | $54.45B | $53.10B | $51.42B | $49.94B | $48.54B | · | $45.87B | $43.06B | · | |
| Treasury Stock | $26.37B | $25.36B | $22.31B | $22.31B | $21.27B | $21.27B | $19.23B | $18.23B | $18.19B | $18.19B | · | $15.12B | $15.08B | · | |
| AOCI | $-2.46B | $-2.50B | $-2.45B | $-2.80B | $-2.80B | $-2.34B | $-2.70B | $-2.48B | $-2.41B | $-2.76B | · | $-3.03B | $-3.05B | · | |
| Stockholders' Equity | $52.68B | $51.93B | $53.41B | $51.02B | $50.51B | $49.39B | $49.58B | $48.99B | $47.43B | $45.52B | · | $45.33B | $42.26B | · | |
| Liabilities + Equity | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | · | $97.06B | $94.66B | · | |
| Shares Outstanding | 446,000,000 | 445,000,000 | 445,000,000 | 445,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 443,000,000 | 443,000,000 | 442,000,000 | 442,000,000 | 441,000,000 | 441,000,000 |
Грошовий потік 16
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $82M | $83M | $84M | $70M | $81M | $75M | $79M | $68M | $84M | $70M | $61M | $67M | $76M | $75M | |
| Deferred Tax | $-208M | $-258M | $89M | $-127M | $-322M | $-279M | $-202M | $-400M | · | · | · | · | · | · | |
| Amort. of Intangibles | $485M | $430M | $436M | $435M | $430M | $429M | $438M | $449M | $514M | $551M | $563M | $584M | $606M | $592M | |
| Restructuring | $38M | $34M | $36M | $62M | $56M | $43M | $20M | $26M | $26M | $25M | $19M | $38M | $50M | $37M | |
| Operating Cash Flow | $2.12B | $1.19B | $3.46B | $2.24B | $1.40B | $723M | $3.29B | $2.17B | $1.96B | $1.25B | $3.72B | $2.41B | $729M | $3.49B | |
| CapEx | $450M | $376M | $465M | $404M | $294M | $362M | $480M | $272M | $301M | $347M | $405M | $332M | $458M | $550M | |
| Investing Cash Flow | $164M | $-8.96B | $891M | $-4.12B | $-288M | $-527M | $20M | $-3.58B | $-253M | $-2.03B | $-376M | $-1.18B | $-3.14B | $-525M | |
| Debt Issued | $0 | $5.24B | $4.92B | $0 | $0 | $2.84B | $0 | $0 | $-1M | $1.21B | $2.48B | $3.47B | $0 | $3.19B | |
| Net Debt Issued | · | $3.83B | · | · | · | $2.00B | · | · | · | $1.21B | · | · | $0 | · | |
| Stock Repurchased | $1.00B | $3.00B | $37M | $963M | $0 | $2.00B | $1.00B | $0 | $0 | $3.00B | $0 | $0 | $3.00B | $1.00B | |
| Net Stock Activity | · | $-3.00B | · | · | · | $-2.00B | · | · | · | $-3.00B | · | · | $-3.00B | · | |
| Dividends Paid | $175M | $162M | $162M | $163M | $162M | $149M | $149M | $150M | $149M | $135M | $136M | $135M | $117M | $117M | |
| Financing Cash Flow | $-1.57B | $1.09B | $3.53B | $-632M | $-991M | $-102M | $-3.67B | $-1.19B | $-115M | $-1.82B | $-1.43B | $1.85B | $-2.59B | $2.39B | |
| Net Change in Cash | $817M | $-6.60B | $7.87B | $-2.59B | $431M | $132M | $-630M | $-2.43B | $1.58B | $-2.58B | $1.93B | $3.02B | $-5.04B | $5.60B | |
| Free Cash Flow | · | $816M | · | · | · | $361M | · | · | · | $904M | · | · | $271M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $605M | · | · | $-19M | · |
Прибутковість 7
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| Net Margin | 14.5% | 15.0% | · | 14.5% | 14.9% | 14.6% | · | 15.4% | 14.7% | 12.9% | · | 16.0% | 12.1% | · | |
| Pretax Margin | 16.0% | 15.8% | · | 16.4% | 15.7% | 15.6% | · | 16.4% | 16.7% | 15.4% | · | 16.7% | 12.7% | · | |
| EBITDA Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| ROA | 1.6% | 1.6% | · | 1.6% | 1.6% | 1.5% | · | 1.7% | 1.6% | 1.4% | · | 1.8% | · | · | |
| ROE | 3.4% | 3.3% | · | 3.2% | 3.3% | 3.2% | · | 3.5% | 3.4% | 3.0% | · | 3.8% | · | · | |
| ROIC | 3.6% | 3.4% | · | 3.4% | 3.4% | 3.3% | · | 3.5% | 3.6% | 3.0% | · | 4.0% | · | · |
Ліквідність та платоспроможність 3
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.5 | · | 1.5 | 1.9 | 1.8 | · | 1.6 | 1.7 | 1.7 | · | 1.6 | · | · | |
| Quick Ratio | 0.9 | 0.9 | · | 0.8 | 1.2 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 4.6 | · | 5.2 | 5.2 | · |
Ефективність 2
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · |
Оцінка (TTM) 10
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.98B | $43.35B | · | $42.94B | $42.36B | $41.85B | · | $42.06B | $42.15B | $42.32B | · | $42.65B | $44.17B | · | |
| Net Income TTM | $6.62B | $6.39B | · | $6.37B | $6.31B | $6.02B | · | $6.20B | $5.94B | $5.68B | · | $5.85B | $6.68B | · | |
| Market Cap | $228.81B | $210.65B | · | $206.59B | $181.28B | $222.07B | · | $272.80B | $244.98B | $257.48B | · | $223.73B | · | · | |
| P/E | 29.1 | 27.9 | · | 27.7 | 24.7 | 31.8 | · | 38.0 | 35.8 | 39.5 | · | 33.7 | 34.0 | · | |
| P/S | 5.1 | 4.9 | · | 4.8 | 4.3 | 5.3 | · | 6.5 | 5.8 | 6.1 | · | 5.2 | · | · | |
| P/B | 4.3 | 4.1 | · | 4.0 | 3.6 | 4.5 | · | 5.6 | 5.2 | 5.7 | · | 4.9 | · | · | |
| P / Cash Flow | · | 176.7 | · | · | · | 307.2 | · | · | · | 205.8 | · | · | · | · | |
| P / FCF | · | 258.1 | · | · | · | 615.2 | · | · | · | 284.8 | · | · | · | · | |
| Earnings Yield | 3.4% | 3.6% | · | 3.6% | 4.0% | 3.1% | · | 2.6% | 2.8% | 2.5% | · | 3.0% | 2.9% | · | |
| Payout Ratio | · | 9.8% | · | · | · | 9.9% | · | · | · | 10.1% | · | · | 9.1% | · |
Фінансова звітність Звіт про прибутки та збитки, баланс, рух грошових коштів — річні, за останні 5 років
Звіт про прибутки та збитки
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Виручка | $44.56B | — | — | $42.88B | — |
| Операційна маржа % | 17.4% | — | — | 17.1% | — |
| Чистий прибуток | $6.70B | — | — | $6.33B | — |
| Розбавлений EPS | $17.74 | — | — | $16.53 | — |
Баланс
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Поточний коефіцієнт | 1.9 | — | — | 1.7 | — |
| Коефіцієнт швидкої ліквідності | 1.3 | — | — | 1.0 | — |
Грошовий потік
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Вільний грошовий потік | $6.29B | — | — | $7.27B | — |
Останні новини Останні заголовки, що згадують цю компанію
- Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
- Чи подобається аналітикам Уолл-стріт акції Thermo Fisher Scientific?
- Thermo Fisher Scientific Inc. (TMO) відкриває Центр дизайну біопроцесів для розробки терапій, що змінюють життя
- Джим Крамер про Thermo Fisher: «Я думаю, що ви можете купити її на цьому рівні»
- TD Cowen знижує цільову ціну Thermo Fisher (TMO), зберігає рейтинг "Купувати"
Мої показники Ваш персональний список спостереження — вибрані рядки з Повних фундаментальних даних
Виберіть показники, які для вас важливі — натисніть ➕ поруч із будь-яким рядком у Повних фундаментальних даних вище.
Ваш вибір збережено і він буде застосовуватися до всіх тікерів.
Інституційні власники (13F) 2 893 подавачі звітності · $107.2B всього · Станом на 30 червня 2026 р.
Інституційні інвестори, які звітують про володіння цими акціями у своїй квартальній формі SEC 13F. Тільки довгі позиції; один подавець звітності може з'явитися двічі для окремих опціонних контрактів. Великі протилежні опціонні позиції (пут/кол) зазвичай відображають маркет-мейкінг або хеджування запасів, а не спрямованість переконань.
| Нові позиції | Закриті позиції | Збільшено | Зменшено | Зміна чистих акцій |
|---|---|---|---|---|
| 196 (-8 проти попереднього кв.) | 140 (-75 проти попереднього кв.) | 929 (-39 проти попереднього кв.) | 1 121 (+28 проти попереднього кв.) | +25.6M |
Порівняно з Q1 2026. Звіти SEC Form 13F подаються протягом 45 днів після закінчення кварталу плюс невеликий буфер для тих, хто подає із запізненням — квартали, що ще знаходяться в цьому вікні, пропускаються на користь останньої повністю звітної пари.
| Інституційний інвестор | Вартість | Акції | % від відстежуваного 13F | Тип |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $12 171 173 789 | 24 276 316 | 11,35% | Акції |
| STATE STREET CORP | $8 443 627 719 | 16 825 879 | 7,88% | Акції |
| FMR LLC | $4 526 822 682 | 9 029 086 | 4,22% | Акції |
| GEODE CAPITAL MANAGEMENT, LLC | $3 572 029 397 | 7 164 352 | 3,33% | Акції |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3 121 552 090 | 6 226 169 | 2,91% | Акції |
| Capital World Investors | $3 106 193 041 | 6 195 370 | 2,90% | Акції |
| NORGES BANK | $2 550 871 048 | 5 087 903 | 2,38% | Акції |
| Capital Research Global Investors | $2 079 461 815 | 4 147 545 | 1,94% | Акції |
| Capital International Investors | $1 595 416 232 | 3 182 151 | 1,49% | Акції |
| Dodge & Cox | $1 531 543 498 | 3 054 778 | 1,43% | Акції |
| Fisher Asset Management, LLC | $1 461 823 432 | 2 915 715 | 1,36% | Акції |
| Grantham, Mayo, Van Otterloo & Co. LLC | $1 373 321 891 | 2 739 191 | 1,28% | Акції |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1 371 130 859 | 2 734 823 | 1,28% | Акції |
| EdgePoint Investment Group Inc. | $1 092 789 324 | 2 179 650 | 1,02% | Акції |
| VANGUARD FIDUCIARY TRUST CO | $1 046 130 256 | 2 086 585 | 0,98% | Акції |
| Unisphere Establishment | $1 032 801 600 | 2 060 000 | 0,96% | Акції |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1 009 204 590 | 2 012 934 | 0,94% | Акції |
| PRIMECAP MANAGEMENT CO/CA/ | $993 831 390 | 1 982 271 | 0,93% | Акції |
| VIKING GLOBAL INVESTORS LP | $971 342 384 | 1 937 415 | 0,91% | Акції |
| FLOSSBACH VON STORCH SE | $955 579 626 | 1 905 975 | 0,89% | Акції |
| ALLIANCEBERNSTEIN L.P. | $908 857 157 | 1 849 037 | 0,85% | Акції |
| 1832 Asset Management L.P. | $863 062 662 | 1 721 443 | 0,81% | Акції |
| Clearbridge Investments, LLC | $847 834 531 | 1 691 069 | 0,79% | Акції |
| PARNASSUS INVESTMENTS, LLC | $822 024 341 | 1 639 589 | 0,77% | Акції |
| DIMENSIONAL FUND ADVISORS LP | $768 919 799 | 1 533 667 | 0,72% | Акції |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $667 185 605 | 1 330 750 | 0,62% | Акції |
| Temasek Holdings (Private) Ltd | $583 447 171 | 1 163 729 | 0,54% | Акції |
| BlackRock, Inc. | $579 344 543 | 1 155 546 | 0,54% | Акції |
| LOOMIS SAYLES & CO L P | $571 001 278 | 1 138 905 | 0,53% | Акції |
| LAZARD ASSET MANAGEMENT LLC | $567 301 499 | 1 131 525 | 0,53% | Акції |
| Sumitomo Mitsui Trust Group, Inc. | $541 170 491 | 1 079 405 | 0,50% | Акції |
| Pictet Asset Management Holding SA | $538 406 962 | 1 073 670 | 0,50% | Акції |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $526 019 392 | 1 049 185 | 0,49% | Акції |
| Swiss National Bank | $525 485 443 | 1 048 120 | 0,49% | Акції |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $505 067 056 | 1 007 394 | 0,47% | Акції |
| Rathbones Group PLC | $504 097 425 | 1 005 460 | 0,47% | Акції |
| UBS Group AG | $503 596 066 | 1 004 460 | 0,47% | Акції |
| BANK OF AMERICA CORP /DE/ | $488 690 042 | 974 729 | 0,46% | Акції |
| WELLINGTON MANAGEMENT GROUP LLP | $450 916 165 | 899 386 | 0,42% | Акції |
| Veritas Asset Management LLP | $442 637 207 | 882 873 | 0,41% | Акції |
| Focus Partners Wealth | $431 444 332 | 860 536 | 0,40% | Акції |
| FIRST MANHATTAN CO. LLC. | $422 447 886 | 841 894 | 0,39% | Акції |
| National Pension Service | $422 118 548 | 841 947 | 0,39% | Акції |
| GOLDMAN SACHS GROUP INC | $417 251 345 | 832 239 | 0,39% | Акції |
| D1 Capital Partners L.P. | $409 672 787 | 817 123 | 0,38% | Акції |
| W1M Asset Management Ltd | $408 009 352 | 814 886 | 0,38% | Акції |
| Vanguard Global Advisers, LLC | $401 921 762 | 801 663 | 0,37% | Акції |
| Legal & General Group Plc | $393 992 751 | 785 848 | 0,37% | Акції |
| BARCLAYS PLC | $383 005 951 | 763 934 | 0,36% | Акції |
| AMERIPRISE FINANCIAL INC | $373 268 191 | 744 431 | 0,35% | Акції |
| BNP PARIBAS FINANCIAL MARKETS | $369 918 950 | 737 831 | 0,35% | Акції |
| VANGUARD ASSET MANAGEMENT, Ltd | $365 892 528 | 729 800 | 0,34% | Акції |
| VANGUARD GROUP INC | $354 408 424 | 611 629 | 0,33% | Акції |
| California Public Employees Retirement System | $349 327 092 | 696 759 | 0,33% | Акції |
| KING LUTHER CAPITAL MANAGEMENT CORP | $339 577 646 | 677 313 | 0,32% | Акції |
| W1M Investment Management Ltd | $335 034 706 | 691 342 | 0,31% | Акції |
| NEUBERGER BERMAN GROUP LLC | $321 963 477 | 642 176 | 0,30% | Акції |
| RAYMOND JAMES FINANCIAL INC | $319 519 265 | 637 305 | 0,30% | Акції |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $314 473 046 | 627 240 | 0,29% | Акції |
| VICTORY CAPITAL MANAGEMENT INC | $309 344 243 | 616 961 | 0,29% | Акції |
| CANADA PENSION PLAN INVESTMENT BOARD | $307 944 336 | 614 218 | 0,29% | Акції |
| D. E. Shaw & Co., Inc. | $307 017 322 | 612 369 | 0,29% | Акції |
| JANUS HENDERSON GROUP PLC | $301 030 667 | 612 436 | 0,28% | Акції |
| RHUMBLINE ADVISERS | $297 780 694 | 593 946 | 0,28% | Акції |
| Ninety One UK Ltd | $297 641 362 | 593 668 | 0,28% | Акції |
| ENVESTNET ASSET MANAGEMENT INC | $296 956 107 | 592 301 | 0,28% | Акції |
| Mirova US LLC | $296 432 610 | 591 257 | 0,28% | Акції |
| Robeco Institutional Asset Management B.V. | $289 599 072 | 577 627 | 0,27% | Акції |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $281 062 261 | 571 811 | 0,26% | Акції |
| PRINCIPAL FINANCIAL GROUP INC | $274 562 786 | 547 636 | 0,26% | Акції |
| Eurizon Capital SGR S.p.A. | $271 488 657 | 539 965 | 0,25% | Акції |
| APG Asset Management N.V. | $266 543 464 | 607 825 | 0,25% | Акції |
| Longview Partners (Guernsey) LTD | $265 608 495 | 529 776 | 0,25% | Акції |
| CITADEL ADVISORS LLC | $263 486 238 | 525 543 | 0,25% | Акції |
| Lindsell Train Ltd | $257 955 736 | 514 512 | 0,24% | Акції |
| Southpoint Capital Advisors LP | $250 680 000 | 500 000 | 0,23% | Акції |
| Qube Research & Technologies Ltd | $246 959 909 | 492 580 | 0,23% | Акції |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | $245 733 399 | 490 134 | 0,23% | Акції |
| CI INVESTMENTS INC. | $235 771 058 | 470 263 | 0,22% | Акції |
| Balyasny Asset Management L.P. | $225 425 494 | 449 628 | 0,21% | Акції |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $223 014 454 | 444 819 | 0,21% | Акції |
| JONES FINANCIAL COMPANIES LLLP | $221 174 247 | 431 114 | 0,21% | Акції |
| ROYAL LONDON ASSET MANAGEMENT LTD | $217 246 307 | 433 314 | 0,20% | Акції |
| M&G PLC | $214 820 283 | 428 783 | 0,20% | Акції |
| Cryder Capital Partners LLP | $210 160 586 | 419 181 | 0,20% | Акції |
| FIFTH THIRD BANCORP | $209 624 364 | 418 112 | 0,20% | Акції |
| JANE STREET GROUP, LLC | $205 206 648 | 409 300 | 0,19% | Опціон пут |
| JANE STREET GROUP, LLC | $204 905 832 | 408 700 | 0,19% | Опціон кол |
| Ensign Peak Advisors, Inc | $204 085 607 | 407 064 | 0,19% | Акції |
| NEW YORK STATE COMMON RETIREMENT FUND | $203 978 817 | 406 851 | 0,19% | Акції |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $203 629 369 | 406 154 | 0,19% | Акції |
| AVIVA PLC | $202 744 469 | 404 389 | 0,19% | Акції |
| Navera Investment Management Ltd. | $199 087 273 | 397 439 | 0,19% | Акції |
| FIL Ltd | $198 044 720 | 395 015 | 0,18% | Акції |
| CIBC Bancorp USA Inc. | $190 068 606 | 378 891 | 0,18% | Акції |
| Alyeska Investment Group, L.P. | $188 546 957 | 376 071 | 0,18% | Акції |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $187 568 351 | 373 510 | 0,17% | Акції |
| Liontrust Investment Partners LLP | $181 599 110 | 362 213 | 0,17% | Акції |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $180 518 000 | 360 056 | 0,17% | Акції |
| Railway Pension Investments Ltd | $179 973 199 | 358 970 | 0,17% | Акції |
Інсайдери компанії 60 інсайдерів · 29 керівники · 28 директори
| Інсайдер | Роль | Остання активність | Кількість акцій у власності | Купівлі за 12 міс. | Продажі за 12 міс. | Нетто 12 міс |
|---|---|---|---|---|---|---|
| Marijn E Dekkers | Chief Executive Officer | 17 серпня 2009 р. F | 42 554 | 0 | 0 | $0 |
| Stephen Williamson | Retiring Sr. VP and CFO | 28 лютого 2026 р. F | 32 499 | 0 | 0 | $0 |
| Kyriazi Theo Melas | VP & Chief Financial Officer | 16 вересня 2004 р. M | 158 199 | 0 | 0 | $0 |
| Gianluca Pettiti | President & COO | 27 липня 2026 р. S | 24 651 | 0 | 6 | $-2 582 704 |
| Mark Stevenson | Retiring Executive VP & COO | 25 лютого 2022 р. F | 62 141 | 0 | 0 | $0 |
| Frederick M. Lowery | Executive Vice President | 28 лютого 2026 р. F | 15 044 | 0 | 2 | $-8 154 131 |
| Michel Lagarde | Executive Vice President | 28 лютого 2026 р. F | 85 151 | 0 | 5 | $-51 307 290 |
| Thomas B Shropshire Jr. | SVP and General Counsel | 25 лютого 2026 р. A | 6 058 | 0 | 0 | $0 |
| Michael A Boxer | SVP and General Counsel | 10 березня 2025 р. S | 10 816 | 0 | 0 | $0 |
| Syed A. Jafry | Sr. Vice President | 26 лютого 2021 р. F | 22 349 | 0 | 0 | $0 |
| Peter E Hornstra | VP & Chief Accounting Officer | 26 лютого 2021 р. F | 1 962 | 0 | 0 | $0 |
| Patrick M Durbin | Senior Vice President | 28 серпня 2019 р. F | 38 868 | 0 | 0 | $0 |
| Gregory J. Herrema | Senior Vice President | 28 серпня 2019 р. F | 26 967 | 0 | 0 | $0 |
| Seth H Hoogasian | Sr. VP & Retiring Gen. Counsel | 28 лютого 2018 р. F | 26 530 | 0 | 0 | $0 |
| Shine Daniel P | Senior Vice President | 30 серпня 2017 р. S | 20 682 | 0 | 0 | $0 |
| Thomas W Loewald | Senior Vice President | 28 серпня 2017 р. F | 38 133 | 0 | 0 | $0 |
| Peter M Wilver | Exec. VP & Chief Admin Officer | 15 березня 2017 р. S | 62 517 | 0 | 0 | $0 |
| Alan J Malus | Executive Vice President | 10 березня 2016 р. M | 47 286 | 0 | 0 | $0 |
| Andrew J Thomson | Senior Vice President | 26 серпня 2015 р. F | 52 389 | 0 | 0 | $0 |
| Edward A Pesicka | Senior Vice President | 05 березня 2015 р. M | 80 641 | 0 | 0 | $0 |
| Kenneth Berger | Senior Vice President | 26 лютого 2012 р. F | 36 128 | 0 | 0 | $0 |
| Stephen G Sheehan | Sr. VP, Human Resources | 05 березня 2010 р. F | 4 396 | 0 | 0 | $0 |
| Yuh-Geng Tsay | Senior Vice President | 26 лютого 2010 р. F | 110 369 | 0 | 0 | $0 |
| Alexander G Stachtiaris | Sr. VP, Global Bus. Services | 05 березня 2008 р. A | 17 236 | 0 | 0 | $0 |
| Fredric T Walder | Sr. VP, Customer Excellence | 05 березня 2008 р. A | 16 730 | 0 | 0 | $0 |
| Guy Broadbent | Senior Vice President | 05 березня 2008 р. A | 31 545 | 0 | 0 | $0 |
| Joseph R Massaro | Sr. VP, Global Bus. Services | 16 листопада 2007 р. S | 15 000 | 0 | 0 | $0 |
| SYRON RICHARD F/CA | Executive Chairman | 12 грудня 2003 р. S | 80 320 | 0 | 0 | $0 |
| Barry S Howe | VP, Measurement & Control | 31 липня 2003 р. M | 23 247 | 0 | 0 | $0 |
| Alexandra R. Keith | Директор | 27 червня 2026 р. A | 2 602 | 0 | 0 | $0 |
| Dion J Weisler | Директор | 27 червня 2026 р. A | 5 446 | 0 | 0 | $0 |
| Karen S Lynch | Директор | 27 червня 2026 р. A | 1 159 | 0 | 0 | $0 |
| Scott M Sperling | Директор | 27 червня 2026 р. A | 69 479 | 0 | 0 | $0 |
| Jennifer M Johnson | Директор | 27 червня 2026 р. A | 1 403 | 0 | 0 | $0 |
| Debora L Spar | Директор | 20 травня 2026 р. A | 2 610 | 0 | 0 | $0 |
| Tyler Jacks | Директор | 20 травня 2026 р. A | 9 462 | 0 | 0 | $0 |
| Ruby R Chandy | Директор | 20 травня 2026 р. A | 3 463 | 0 | 0 | $0 |
| Nelson Chai | Директор | 20 травня 2026 р. A | 15 316 | 0 | 0 | $0 |
| Martin C Harris | Директор | 20 травня 2026 р. A | 9 532 | 0 | 0 | $0 |
| MULLEN JAMES C | Директор | 21 травня 2025 р. A | 3 393 | 0 | 0 | $0 |
| Lars Rebien Sorensen | Директор | 22 травня 2024 р. F | 9 233 | 0 | 0 | $0 |
| Jim P Manzi | Директор | 03 лютого 2023 р. S | 14 807 | 0 | 0 | $0 |
| Thomas J Lynch | Директор | 05 листопада 2021 р. G | 10 257 | 0 | 0 | $0 |
| Judy C Lewent | Директор | 20 травня 2020 р. A | 1 290 | 0 | 0 | $0 |
| Elaine Ullian | Директор | 22 травня 2019 р. A | 4 706 | 0 | 0 | $0 |
| William G Parrett | Директор | 23 лютого 2018 р. S | 11 660 | 0 | 0 | $0 |
| Michael E Porter | Директор | 09 березня 2012 р. M | 14 640 | 0 | 0 | $0 |
| Peter J Manning | Директор | 25 травня 2011 р. A | 6 548 | 0 | 0 | $0 |
| Michael Adam Bell | Директор | 20 травня 2010 р. A | 8 192 | 0 | 0 | $0 |
| Stephen P Kaufman | Директор | 20 травня 2010 р. A | 9 192 | 0 | 0 | $0 |
Інсайдери згідно з формами SEC 3/4/5; чистий результат = лише відкритий ринок купівлі/продажу
Активісти та власники %+ 5 22 холдинги
Інвестори, які подали Розклад SEC 13D — бенефіціарна власність понад 5% з наміром вплинути на емітента (активістські частки, кампанії в раді директорів, M&A). Кожен рядок показує останній відомий стан позиції цього подавця.
| Подавець | Подано | Частка | Статус | Мета | Подача |
|---|---|---|---|---|---|
| Pharmaceutical Product Development, LLC, Wildcat Acquisition Holdings (UK) Limited, Jaguar Holding Company II, Jaguar Holding Company I, LLC, Eagle Holding Company II, LLC, PPD, Inc., Thermo Fisher Scientific Powder US Holdings Corp., Thermo Fisher Scientific Inc., Fisher Scientific International LLC, Fisher Scientific Worldwide Inc., Spectra-Physics Holdings USA, LLC, Thermo Fisher Scientific Powder Holdings I Ltd, Thermo Fisher Scientific Powder Holdings II Ltd, Thermo Fisher Scientific Powder Holdings III Ltd, Thermo Fisher Scientific Powder Holdings IV Ltd, Thermo Fisher Scientific Powder US Holdings Ltd ×2 подання | 14 березня 2024 р. | — | Первинна подача | M&A / продаж | SEC |
| Thermo Fisher Scientific Inc., Thermo Fisher (CN) Luxembourg S.à r.l. ×2 подання | 13 вересня 2017 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 30 червня 2005 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 11 травня 2005 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 24 березня 2005 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 02 березня 2005 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 28 липня 2004 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 27 липня 2004 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 28 жовтня 2003 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 17 жовтня 2002 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 16 жовтня 2002 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 04 квітня 2002 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 01 квітня 2002 р. | — | Первинна подача | — | SEC |
| Thermo Electron Corporation IRS No. ×5 подання | 27 грудня 2001 р. | — | Первинна подача | — | SEC |
| Нерозкрита особа, що звітує | 21 листопада 2001 р. | — | Первинна подача | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Присутність в ETF Належить 212 ETF
Вага відображає лише прямі акціонерні володіння (N-PORT); фонди з кредитним плечем або похідними інструментами можуть мати додаткову експозицію за свопами, яка не відображається.
| Фонд | Вага | Одиниці | Станом на | Джерело |
|---|---|---|---|---|
| GDOC · Goldman Sachs ETF Trust | 4,52% | 1 847 NS | 31 травня 2026 р. | N-PORT |
| AGIQ · Tidal Trust I | 3,99% | 918 NS | 31 травня 2026 р. | N-PORT |
| HRTS · Tema ETF Trust | 3,97% | 4 185 NS | 31 травня 2026 р. | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,19% | 740 NS | 30 квітня 2026 р. | N-PORT |
| PRVS · Parnassus Funds II | 3,12% | 1 576 NS | 30 червня 2026 р. | N-PORT |
| QLTY · GMO ETF Trust | 2,94% | 269 227 NS | 31 травня 2026 р. | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 2,91% | 173 204 NS | 30 квітня 2026 р. | N-PORT |
| RXL · ProShares Trust | 2,68% | 3 918 NS | 31 травня 2026 р. | N-PORT |
| EQTY · Valued Advisers Trust | 2,66% | 72 927 NS | 30 квітня 2026 р. | N-PORT |
| TOLL · Tema ETF Trust | 2,63% | 2 616 NS | 31 травня 2026 р. | N-PORT |
| CURE · Direxion Shares ETF Trust | 2,59% | 7 491 NS | 30 квітня 2026 р. | N-PORT |
| QIDX · Spinnaker ETF Series | 2,39% | 1 916 NS | 30 квітня 2026 р. | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,99% | 2 213 NS | 30 квітня 2026 р. | N-PORT |
| CAML · Professionally Managed Portfolios | 1,88% | 14 779 NS | 30 квітня 2026 р. | N-PORT |
| PEXL · Pacer Funds Trust | 1,67% | 1 592 NS | 30 квітня 2026 р. | N-PORT |
| FMCE · Northern Lights Fund Trust IV | 1,64% | 2 250 NS | 31 травня 2026 р. | N-PORT |
| FMCX · Northern Lights Fund Trust IV | 1,63% | 3 902 NS | 31 травня 2026 р. | N-PORT |
| FMED · Fidelity Covington Trust | 1,53% | 1 276 NS | 31 травня 2026 р. | N-PORT |
| BKDV · BNY Mellon ETF Trust II | 1,43% | 41 397 NS | 30 квітня 2026 р. | N-PORT |
| LCAP · Principal Exchange-Traded Funds | 1,43% | 52 103 NS | 30 червня 2026 р. | N-PORT |
| RILA · Spinnaker ETF Series | 1,32% | 1 154 NS | 30 квітня 2026 р. | N-PORT |
| SNPV · DBX ETF Trust | 1,26% | 5 900 NS | 29 травня 2026 р. | N-PORT |
| ALRG · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1,22% | 189 NS | 30 квітня 2026 р. | N-PORT |
| LRGC · AB Active ETFs, Inc. | 1,20% | 30 508 NS | 31 травня 2026 р. | N-PORT |
| MFSG · MFS Active Exchange Traded Funds Tr… | 1,16% | 8 091 NS | 31 травня 2026 р. | N-PORT |
| WBIF · Absolute Shares Trust | 1,11% | 519 NS | 30 червня 2026 р. | N-PORT |
| RFFC · ALPS ETF Trust | 1,08% | 654 NS | 31 травня 2026 р. | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 1,02% | 3 416 NS | 30 квітня 2026 р. | N-PORT |
| FFND · Northern Lights Fund Trust II | 1,02% | 2 122 NS | 31 травня 2026 р. | N-PORT |
| CRTC · DBX ETF Trust | 0,85% | 2 247 NS | 31 травня 2026 р. | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,84% | 15 398 NS | 30 квітня 2026 р. | N-PORT |
| WBIG · Absolute Shares Trust | 0,81% | 443 NS | 30 червня 2026 р. | N-PORT |
| ZECP · Zacks Trust | 0,80% | 5 541 NS | 31 травня 2026 р. | N-PORT |
| TAX · EA Series Trust | 0,79% | 408 NS | 29 травня 2026 р. | N-PORT |
| BIGY · Tidal Trust II | 0,75% | 409 NS | 30 квітня 2026 р. | N-PORT |
| OEI · Listed Funds Trust | 0,75% | 656 NS | 30 квітня 2026 р. | N-PORT |
| FFLC · FIDELITY COVINGTON TRUST | 0,72% | 16 950 NS | 30 квітня 2026 р. | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,71% | 1 284 NS | 30 квітня 2026 р. | N-PORT |
| LOWV · AB Active ETFs, Inc. | 0,66% | 2 747 NS | 31 травня 2026 р. | N-PORT |
| DFLV · Dimensional ETF Trust | 0,66% | 80 920 NS | 30 квітня 2026 р. | N-PORT |
| CGGO · Capital Group Global Growth Equity … | 0,65% | 149 704 NS | 31 травня 2026 р. | N-PORT |
| ADME · ETF Series Solutions | 0,65% | 3 607 NS | 30 квітня 2026 р. | N-PORT |
| ACIO · ETF Series Solutions | 0,65% | 30 940 NS | 30 квітня 2026 р. | N-PORT |
| SCHG · SCHWAB STRATEGIC TRUST | 0,65% | 801 604 NS | 31 травня 2026 р. | N-PORT |
| DFUV · Dimensional ETF Trust | 0,64% | 193 569 NS | 30 квітня 2026 р. | N-PORT |
| FQAL · FIDELITY COVINGTON TRUST | 0,60% | 17 237 NS | 30 квітня 2026 р. | N-PORT |
| ACLC · AMERICAN CENTURY ETF TRUST | 0,59% | 3 667 NS | 31 травня 2026 р. | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0,56% | 3 705 NS | 30 квітня 2026 р. | N-PORT |
| GVUS · Goldman Sachs ETF Trust | 0,55% | 4 581 NS | 31 травня 2026 р. | N-PORT |
| CHRI · Global X Funds | 0,54% | 58 NS | 30 квітня 2026 р. | N-PORT |